Pharming Group (NASDAQ:PHAR) Short Interest Down 47.2% in February

Pharming Group (NASDAQ:PHAR) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 2,800 shares, a decrease of 47.2% from the February 13th total of 5,300 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 7,100 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Ratings Changes

A number of brokerages recently issued reports on PHAR. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Friday.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Stock Performance

PHAR stock traded up $0.03 during midday trading on Friday, hitting $8.77. The stock had a trading volume of 2,836 shares, compared to its average volume of 6,197. Pharming Group has a 52 week low of $6.65 and a 52 week high of $11.80. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The stock has a 50-day simple moving average of $8.99 and a 200 day simple moving average of $8.58. The firm has a market capitalization of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, equities research analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.